HIF1A and neoplasm: Furthermore, HIF-1α and HIF-2α induce resistance to Sorafenib: after a prolonged period of administration, Sorafenib induces hypoxia in the tumor, leading to the expression of HIF-1α and NF-κB in a cellular clone more resistant to the hypoxic environment, thereby resistant to Sorafenib [117].